Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as $102.37 and last traded at $101.28, with a volume of 1171988 shares. The stock had previously closed at $98.64.
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on DNTH. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Monday, April 20th. Wedbush increased their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Wells Fargo & Company started coverage on Dianthus Therapeutics in a research note on Thursday, March 19th. They set an “overweight” rating and a $135.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $117.82.
Read Our Latest Research Report on DNTH
Dianthus Therapeutics Price Performance
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.
Insider Activity
In related news, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the transaction, the executive vice president owned 31,249 shares in the company, valued at approximately $3,157,086.47. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Adam M. Veness sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the transaction, the senior vice president directly owned 30,000 shares in the company, valued at approximately $2,424,000. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 87,779 shares of company stock worth $7,985,235 in the last three months. 3.02% of the stock is owned by insiders.
Institutional Trading of Dianthus Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP grew its position in Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after acquiring an additional 1,499,931 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares in the last quarter. TCG Crossover Management LLC increased its position in Dianthus Therapeutics by 11.7% during the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after buying an additional 175,000 shares during the last quarter. Finally, State Street Corp increased its position in Dianthus Therapeutics by 124.7% during the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after buying an additional 836,571 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.
Dianthus Therapeutics Company Profile
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Read More
- Five stocks we like better than Dianthus Therapeutics
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
